EUCTR2019-000598-22-DE进行中（未招募）1 期
Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki) - TraSki
niversity Hospital Schleswig Holstein, Represented by the Board of Directors which is represented by the chairman0 个研究点目标入组 16 人开始时间: 2020年4月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Written informed consent obtained from the subject prior to performing any protocol-related procedures, including screening Evaluations.
- •2.Age = 18 years at time of study entry.
- •3.Diagnosis of chronic atopic dermatitis for at least 1 year prior to enrollment based on American Academy Criteria.
- •4.Subjects who have a recent history (within 1 year before the screening visit) of inadequate response to treatment with topical medications. Inadequate response is defined as failure to achieve and maintain remission or a low disease activity state (comparable to IGA 0=clear to 2=mild) despite treatment with a daily regimen of TCS of medium to higher potency (±TCI as appropriate), applied for at least 28 days or for the maximum duration recommended by the product prescribing information (e.g. 14 days for super-potent TCS), whichever is shorter. Subjects with documented systemic treatment for AD in the past year are also considered as inadequate responders to topical treatments and are potentially eligible for treatment with Tralokinumab after appropriate washout.
- •5.Eczema Area and Severity Index (EASI) score =12 at screening (Week0 minus 7d) and baseline visit (Week0).
- •6.Investigator Global Assessment (IGA) =3 at screening and baseline visit.
- •7.Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial.
- •8.Female participants who are not capable of bearing children or who use a method of contraception that is medically approved by the health authority of the respective country at Screening.
- •9.Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 6
排除标准
- •1.Subject is unable to provide written informed consent or comply with the protocol.
- •2.Concurrent enrolment in another clinical trial where the subject is receiving an IMP or participation in another clinical trial with investigational product during the last 30 days before inclusion or 7 half-lives of previously used trial medication, whichever is longer.
- •3.Previous enrollment in a Tralokinumab clinical trial.
- •7.Having used immunosuppressive/immunomodulating therapy.
- •8.Treatment of selected skin areas (non-lesional skin at volar forearm and extensor forearm, lesional skin) with topical corticosteroid or topical calcineurin inhibitor 1 week prior to baseline visit and throughout the study.
- •9.Treatment of skin areas of examination with emollients 24 hours prior to baseline visit and throughout the study.
- •11.Dementia or significantly altered mental status that would prohibit the understanding or rendering of information, consent and compliance with the requirements of the protocol and patients who are legally institutionalized.
- •14.Receipt of live attenuated vaccines 30 days prior to the date of baseline and during the trial including the safety follow-up period.
- •15.Receipt of any marketed biological therapy (i.e. immunoglobulin, anti-IgE) including dupilumab or investigational biologic agents:
- •21.History of a helminthic parasitic infection within 6 months prior to the date informed consent is obtained that has not been treated with, or has failed to respond to, standard of care therapy.
- •22.History of anaphylaxis following any biological therapy.
- •23.History of immune complex disease.
- •24.History of cancer:
- •25.History of tuberculosis 26.History of any known primary immunodeficiency disorder including a positive human immunodeficiency virus (HIV) test at screening, or the subject taking antiretroviral medications as determined by medical history and/or subject’s verbal report.
- •27.History of chronic alcohol or drug abuse within 12 months prior to screening, or any condition associated with poor compliance as judged by the investigator.
- •28.Any disorder, including but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, immunological, psychiatric, or major physical impairment that is not stable, in the opinion of the investigator, and could:
- •29.Any clinically significant abnormal findings in physical examination, vital signs, hematology or clinical chemistry during the screening period, which in the opinion of the investigator, may put the subject at risk because of his/her participation in the trial, or may influence the results of the trial, or the subject’s ability to complete entire duration of the trial.
- •30.Positive hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B core antibody (HBcAb) or hepatitis C virus antibody (anti-HCV) serology at screening.
- •31.Pregnant, breastfeeding, or lactating women.
- •32.Employees of the trial site or any other individuals directly involved with the planning or conduct of the trial or immediate family members of such individuals.
研究者
相似试验
已完成
2 期
Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier FunctionAtopic DermatitisNCT04556461Prof. Dr. Stephan Weidinger16
终止
2 期
Effects of Tralokinumab in the Skin: an Immunologic and Molecular InvestigationAtopic DermatitisNCT05378698University of Zurich24
已完成
2 期
Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic DermatitisAtopic DermatitisNCT02347176MedImmune LLC204
已完成
3 期
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3Atopic DermatitisNCT03363854LEO Pharma380
已完成
3 期
Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7Atopic DermatitisNCT03761537LEO Pharma277